SCHEMBL14678434

SCHEMBL14678434

Fc1cnc2[nH]cc(Br)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.47
DYRK1A Q13627 5/20 0.39
CDK2 P24941 4/20 0.39
CLK4 Q9HAZ1 3/20 0.39
CLK2 P49760 2/20 0.39
ROCK2 O75116 2/20 0.39
MAP4K4 O95819 2/20 0.39
HIPK2 Q9H2X6 2/20 0.39
IRAK4 Q9NWZ3 2/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
JAK2 O60674 1/20 0.39
PRKD3 O94806 1/20 0.39
PRKCG P05129 1/20 0.39
INSR P06213 1/20 0.39
CDK1 P06493 1/20 0.39
FES P07332 1/20 0.39
IGF1R P08069 1/20 0.39
ROS1 P08922 1/20 0.39
FGFR1 P11362 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29605509 1.00 AXL (0.47) AXLDYRK1ACDK2CLK4CLK2
SCHEMBL1666074 0.77 JAK2 (0.54) AXLDYRK1ACDK2CLK4CLK2
SCHEMBL91446 0.77 AXL (0.47) AXLDYRK1ACDK2CLK4CLK2
SCHEMBL21893812 0.77 GSK3B (0.56) DYRK1ACDK2CLK4CLK2ROCK2
SCHEMBL1880862 0.77 BRD4 (0.47) AXLDYRK1ACDK2CLK4CLK2
SCHEMBL29928376 0.77 JAK2 (0.54) AXLDYRK1ACDK2CLK4CLK2
SCHEMBL14041214 0.77 MET (0.43) AXLITKGSK3BGSK3ABRAF
SCHEMBL14685266 0.77 CLK1 (0.39) AXLDYRK1ACDK2CLK4CLK2
SCHEMBL14678114 0.77 AXL (0.43) AXLDYRK1ACDK2CLK4CLK2
Hydrochloric Acid SCHEMBL21988122 0.76 GSK3B (0.54) DYRK1ACDK2CLK4CLK2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326772-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER KYORIN SEIYAKU KK (JP) 2025-10-23 US disclosed
US-20250326773-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER KYORIN SEIYAKU KK (JP) 2025-10-23 US disclosed
US-12357631-B2 Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication COCRYSTAL PHARMA, INC. (US) 2025-07-15 US disclosed
EP-3829719-B1 PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION COCRYSTAL PHARMA INC (US) 2025-04-02 EP disclosed
EP-4447954-A1 HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS Icahn School of Medicine at Mount Sinai (US) 2024-10-23 EP disclosed
CN-112638477-B Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication 共晶制药公司 2024-01-26 CN disclosed
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARAMCEUTICA NV (BE) 2023-12-28 US disclosed
US-20230391774-A1 Novel Compounds AC IMMUNE SA (CH) 2023-12-07 US disclosed
US-20230339943-A1 ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES Guangdong Raynovent Biotech Co., Ltd. (CN) 2023-10-26 US disclosed
EP-4244224-A1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2023-09-20 EP disclosed
US-20150191468-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED 2015-07-09 US disclosed
US-9051319-B2 Inhibitors of influenza viruses replication VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-06-09 US disclosed
US-9051319-B2 Inhibitors of influenza viruses replication VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-06-09 US disclosed
US-9051319-B2 Inhibitors of influenza viruses replication VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-06-09 US disclosed
WO-2015073476-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-05-21 WO disclosed
WO-2015073491-A1 FORMULATIONS OF AZAINDOLE COMPOUNDS VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-05-21 WO disclosed
WO-2015073481-A1 METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-05-21 WO disclosed
EP-2739623-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION Vertex Pharmaceuticals Incorporated (US) 2014-06-11 EP disclosed
WO-2013019828-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-07 WO disclosed
WO-2013019828-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416256-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB AXL 4214/4885DYRK1A 1610/4885CDK2 1779/4885
US-20250326772-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER MRGPRX2, MRGPRX1, MRGPRX4 AXL 4764/4885DYRK1A 3635/4885CDK2 4182/4885
US-20230391774-A1 Novel Compounds MAPT, PSEN2, PSEN1 AXL 4680/4885DYRK1A 3446/4885CDK2 1674/4885
US-20250326773-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER MRGPRX2, MRGPRX1, MRGPRX4 AXL 4764/4885DYRK1A 3635/4885CDK2 4182/4885
US-20230339943-A1 ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES ENTPD5, NUDT1, ITPA AXL 1528/4885DYRK1A 1471/4885CDK2 273/4885
US-20150191468-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION ACE, RNASEH1, ACE2 AXL 2067/4885DYRK1A 4168/4885CDK2 316/4885
US-12357631-B2 Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication PIR, PNPO, IDO1 AXL 1316/4885DYRK1A 2922/4885CDK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.